All GLP-one course medicines have boxed warnings about thyroid C-mobile tumors noticed in rodent studies, while this threat hasn't been confirmed in humans. The Find cardiovascular outcomes demo demonstrated that semaglutide actually lessened key adverse cardiovascular occasions by 20%, delivering reassurance about long-phrase cardiovascular safety